Pre-earnings options volume in Iovance Biotherapeutics is 1.8x normal with calls leading puts 18:1. Implied volatility suggests the market is anticipating a move near 10.1%, or 43c, after results are released. Median move over the past eight quarters is 3.3%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IOVA:
- IOVA Upcoming Earnings Report: What to Expect?
- Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
- Iovance Biotherapeutics to present clinical, preclinical data for TIL therapies
- Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
